Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

Check the time stamp on this data. Updated AI-Generated Signals for Biontech Se (BNTX) available here: BNTX. Type a few ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.

Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...